Algernon Phamaceuticals (CSE: AGN)'s CEO said in a brand-new interview last night that they are about to apply to the FDA for Ifenprodil Breakthrough Therapy Designation and Orphan Drug Designation. Click here to see for yourself!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from AGN of US$100,000 cash for a twelve-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.
Preparing Americans for Hyperinflation
